Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice

A. Broccoli, B. Casadei, A. Chiappella, C. Visco, M. Tani, N. Cascavilla, A. Conconi, M. Balzarotti, M.C. Cox, D. Marino, M.C. Goldaniga, R. Marasca, C. Tecchio, C. Patti, G. Musuraca, L. Devizzi, F. Monaco, A. Romano, A. Fama, M. ZancanellaR. Paolini, L. Rigacci, C. Castellino, F. Gaudio, L. Argnani, P.L. Zinzani

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1246-1252
Number of pages7
JournalOncologist
Volume24
Issue number9
DOIs
Publication statusPublished - 2019

Keywords

  • Diffuse large B-cell lymphoma
  • Lenalidomide
  • Real life
  • Refractory
  • Relapsed
  • lenalidomide
  • acute myeloid leukemia
  • adult
  • aged
  • anemia
  • Article
  • cancer chemotherapy
  • cancer recurrence
  • cancer staging
  • diarrhea
  • diffuse large B cell lymphoma
  • disease free survival
  • drug dose reduction
  • drug efficacy
  • drug safety
  • drug tolerability
  • drug withdrawal
  • febrile neutropenia
  • female
  • fever
  • follow up
  • human
  • leukopenia
  • lung infection
  • lymphoma
  • major clinical study
  • male
  • multicenter study
  • multiple cycle treatment
  • nausea
  • neutropenia
  • observational study
  • overall survival
  • patient history of stem cell transplantation
  • priority journal
  • progression free survival
  • retrospective study
  • thrombocytopenia
  • vomiting

Cite this